¹ Department of Neonatology and Centre for Clinical Studies, University of Queensland, Mater Health Services, South Brisbane, Queensland, Australia
² Australian Centre for Paediatric Pharmacokinetics, School of Pharmacy, University of Queensland
³ Neonatal Medicine, Royal Prince Alfred Hospital and Centre for Perinatal Health Services Research, University of Sydney, New South Wales, Australia
⁴ Royal Hobart Hospital, Hobart, Tasmania. Australia
⁵ Mercy Hospital for Women, Melbourne, Victoria, Australia

Correspondence to:
Correspondence to:
Vicki Flenady
Centre for Clinical Studies, Mater Health Services, Raymond Terrace, South Brisbane, Queensland, Australia 4101; vflenady{at}mater.org.au

Objective: To compare two dosing regimens for caffeine citrate in the periextubation period for neonates born at less than 30 weeks gestation in terms of successful extubation and adverse effects.

Design: A multicentre, randomised, double blind, clinical trial.

Setting: Four tertiary neonatal units within Australia.

Patients: Infants born less than 30 weeks gestation ventilated for more than 48 hours.

Interventions: Two dosing regimens of caffeine citrate (20 v 5 mg/kg/day) for periextubation management. Treatment started 24 hours before a planned extubation or within six hours of an unplanned extubation.

Main outcome measure: Failure to extubate within 48 hours of caffeine loading or reintubation and ventilation or doxapram within seven days of caffeine loading.

Results: A total of 234 neonates were enrolled. A significant reduction in failure to extubate was shown for the 20 mg/kg/day dosing group (15.0% v 29.8%; relative risk 0.51; 95% confidence interval (CI) 0.31 to 0.85; number needed to treat 7 (95% CI 4 to 24)). A significant difference in duration of mechanical ventilation was shown for infants of less than 28 weeks gestation receiving the high dose of caffeine (mean (SD) days 14.4 (11.1) v 22.1 (17.1); p  =  0.01). No difference in adverse effects was detected in terms of mortality, major neonatal morbidity, death, or severe disability or general quotient at 12 months.

Conclusions: This trial shows short term benefits for a 20 mg/kg/day dosing regimen of caffeine citrate for neonates born at less than 30 weeks gestation in the periextubation period, without evidence of harm in the first year of life.

Keywords: caffeine; preterm; apnoea; extubation

Relevant Article

Fantoms

Ben Stenson
Arch. Dis. Child. Fetal Neonatal Ed. 2004 89: F471. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A Greenough and M Prendergast Difficult extubation in low birthweight infants Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2008; 93(3): F242 - F245. [Abstract] [Full Text] [PDF]

				G. Natarajan, M.-L. Botica, R. Thomas, and J. V. Aranda Therapeutic Drug Monitoring for Caffeine in Preterm Neonates: An Unnecessary Exercise? Pediatrics, May 1, 2007; 119(5): 936 - 940. [Abstract] [Full Text] [PDF]

				E. Bancalari Caffeine for Apnea of Prematurity N. Engl. J. Med., May 18, 2006; 354(20): 2179 - 2181. [Full Text] [PDF]

				C Hoecker, M Nelle, B Beedgen, J Rengelshausen, and O Linderkamp Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2006; 91(1): F61 - F64. [Abstract] [Full Text] [PDF]